NewsMV
The Schall Law Firm, a Los Angeles-based national shareholder rights litigation firm, is reminding investors of a pending class action lawsuit against Immutep Limited (Nasdaq: IMMP).
The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act. Investors who held IMMP shares are being notified of their opportunity to seek appointment as lead plaintiff in the case.
The Allegations The complaint targets Immutep Limited, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IMMP, under two provisions of federal securities law.
Section 10(b) of the Securities Exchange Act prohibits fraudulent conduct in connection with the purchase or sale of a security, while Section 20(a) extends potential liability to controlling persons of an entity found to have violated the Act.
Keep reading